Skip to main content
ANIP
NASDAQ Life Sciences

ANI Q3 Beats at $2.70 EPS, Cuts Cortrophin Guidance, Launches ~$560M Egetis Offer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$71.72
Mkt Cap
$1.646B
52W Low
$69.58
52W High
$95.57
52W Position info
3.1% above low
Off High info
25% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ANIP is trading near its 52-week low of $69.58 (3.1% above the low).

Summary

ANI beat Q3 estimates with $2.70 adjusted EPS on $290.8M revenue, but trimmed 2026 Cortrophin Gel guidance to $480-$500M on specialty pharmacy capacity constraints while raising EBITDA and EPS targets. It also launched a ~$560M cash offer for Egetis Therapeutics, funded with cash and up to $300M of new JPMorgan bridge debt.


Key Events · Earnings and Guidance · ANIP

  • Q3 Beat on Revenue and EPS

    Net revenues of $290.8M rose 27.6% year-over-year and adjusted non-GAAP diluted EPS of $2.70 beat the $2.18 IBES estimate; GAAP diluted EPS was $1.51.

  • Cortrophin Guidance Cut on Capacity

    2026 Cortrophin Gel revenue guidance was cut to $480-$500M from $520-$540M because specialty pharmacy network capacity is slowing conversion of demand into patients on therapy, despite new gout cases doubling quarter-over-quarter.

  • Total EBITDA and EPS Guidance Raised

    Full-year 2026 revenue guidance narrowed to $1,085-$1,125M, while adjusted non-GAAP EBITDA was raised to $290-$300M and adjusted diluted EPS to $9.37-$9.71.

  • Egetis Offer Terms and Financing

    Cash offer of SEK 11.25 per Egetis share values the deal at about SEK 5.6B (~$560M), or ~$434M enterprise value after Egetis' $190M PRV sale; funded with cash on hand and up to $300M of JPMorgan bridge debt, implying ~2.7x pro forma net leverage.


Analysis · ANIP · Life Sciences

The quarter itself was strong — revenue up 27.6% to $290.8M and adjusted EPS of $2.70 well above the $2.18 consensus — but the guidance mix is the real story. ANI cut its 2026 Cortrophin Gel target to $480-$500M from $520-$540M because specialty pharmacy capacity is throttling conversion of demand into patients on therapy, even as new gout cases doubled quarter-over-quarter. Management offset that with higher total EBITDA ($290-$300M) and EPS ($9.37-$9.71) guidance, so the near-term earnings picture holds. Layered on top is the recommended SEK 11.25/share cash offer for Sweden's Egetis — roughly $560M including incentive programs, or about $434M enterprise value after Egetis' $190M priority review voucher sale — funded with cash on hand plus up to $300M of JPMorgan bridge debt, taking pro forma net leverage to about 2.7x. That deal adds EMCITATE, the only approved MCT8 deficiency therapy, with patent protection into 2045 and over $300M peak sales potential, but management expects it to dilute adjusted EPS in year one. The acceptance period runs roughly November 20 to December 18, 2026 and needs 90% acceptance plus regulatory approvals, so the financing and integration risk lands before the Cortrophin capacity fix does.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANIP was trading at $71.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $69.58 to $95.57. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANIP - Latest Insights

ANIP
Nov 05, 2026, 5:13 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $69.00
Real-time Price: $71.47 info
Change: +$2.47 (+4%) info
Market Cap: $1.624B info
ANIP
Nov 05, 2026, 6:58 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $75.00
Real-time Price: $71.47 info
Change: -$3.53 (-5%) info
Market Cap: $1.624B info
ANIP
Nov 05, 2026, 6:51 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $72.00
Real-time Price: $71.47 info
Change: -$0.530 (-0.74%) info
Market Cap: $1.624B info
ANIP
Nov 05, 2026, 1:33 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $72.00
Real-time Price: $71.47 info
Change: -$0.530 (-0.74%) info
Market Cap: $1.624B info
ANIP
Oct 12, 2026, 6:55 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $73.86
Real-time Price: $71.47 info
Change: -$2.39 (-3%) info
Market Cap: $1.624B info